CombiningDNAVaccine and AIDA-1 in Attenuated Salmonella Activates Tumor-Specific CD4+ and CD8+ T-cell Responses

Cancer Immunology Research

Volumn 5, Issue 6, 2017, Pages 503-514

  Mei, Yu ^a,b   Zhao, Lixiang ^c   Liu, Yonghao ^a   Gong, Huanle ^a   Song, Yuan ^a   Lei, Lei ^a   Zhu, Ying ^a   Jin, Ziqi ^a   Ma, Shoubao ^a   Hu, Bo ^a   Sun, Qing ^d   Liu, Haiyan ^b  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c SOOCHOW UNIVERSITY   (China)

^d YANGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AIDA 1 PROTEIN; CANCER VACCINE; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 6; MELAN A; MELANOMA VACCINE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANKS1B PROTEIN, HUMAN; CARRIER PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; CYTOTOXICITY ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LUNG LAVAGE; LUNG METASTASIS; LYMPHOCYTE PROLIFERATION; MELANOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; SPLEEN; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TH1 CELL; ANIMAL; C57BL MOUSE; GENETICS; IMMUNOLOGY; NEOPLASM; PATHOLOGY; SALMONELLA; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; CANCER VACCINES; CARRIER PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; FEMALE; MICE, INBRED C57BL; NEOPLASMS; SALMONELLA; TUMOR BURDEN; VACCINES, DNA;

EID: 85020681030     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-16-0240-T     Document Type: Article

References (44)

1. Tanaka H, Yoshizawa H, Yamaguchi Y, Ito K, Kagamu H, Suzuki E, et al. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumorprimed lymph node cells. J Immunol 1999;162:3574-82.
2. Koido S, Homma S, Kan S, Takakura K, Namiki Y, Kobayashi H, et al. Induction of antigen-specific cytotoxic T lymphocytes by fusion cells generated from allogeneic plasmacytoid dendritic and tumor cells. Int J Oncol 2014;45:470-8.
3. Janssen EM, Droin NM, Lemmens EE, Pinkoski MJ, Bensinger SJ, Ehst BD, et al. CD4 T-cell help controls CD8 T-cell memory via TRAIL-mediated activation-induced cell death. Nature 2005;434: 88-93.
4. Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003;300:339-42.
5. Flinsenberg TW, Spel L, Jansen M, Koning D, de Haar C, Plantinga M, et al. Cognate CD4 T-cell licensing of dendritic cells heralds anti-cytomegalovirus CD8 T-cell immunity after human allogeneic umbilical cord blood transplantation. J Virol 2015;89:1058-69.
6. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003;300:337-9.
7. Zanetti M. Tapping CD4 T cells for cancer immunotherapy: The choice of personalized genomics. J Immunol 2015;194:2049-56.
8. Ghorashian S, Velica P, Chua I, McNicol AM, Carpenter B, Holler A, et al. CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor. J Immunol 2015;194:1080-9.
9. Dobrzanski MJ. Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy. Front Oncol 2013;3:63.
10. Church SE, Jensen SM, Antony PA, Restifo NP, Fox BA. Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells. Eur J Immunol 2014;44:69-79.
11. Rizos K, Lattemann CT, Bumann D, Meyer TF, Aebischer T. Autodisplay: efficacious surface exposure of antigenic UreA fragments fromHelicobacter pylori in Salmonella vaccine strains. Infect Immun 2003;71:6320-8.
12. Lattemann CT, Maurer J, Gerland E, Meyer TF. Autodisplay: functional display of active beta-lactamase on the surface of Escherichia coli by the AIDA-I autotransporter. J Bacteriol 2000;182:3726-33.
13. Jose J, Maas RM, Teese MG. Autodisplay of enzymes-molecular basis and perspectives. J Biotechnol 2012;161:92-103.
14. Jose J, von Schwichow S. Autodisplay of active sorbitol dehydrogenase (SDH) yields a whole cell biocatalyst for the synthesis of rare sugars. Chembiochem 2004;5:491-9.
15. Gustavsson M, Backlund E, Larsson G. Optimisation of surface expression using the AIDA autotransporter. Microbial Cell Factories 2011;10:72.
16. Jose J, Meyer TF. The autodisplay story, from discovery to biotechnical and biomedical applications. Microbiol Mol Biol Rev 2007;71:600-19.
17. Huang CH, Peng S, He L, Tsai YC, Boyd DA, Hansen TH, et al. Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHCclass I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Ther 2005;12:1180-6.
18. Kutzler MA, Weiner DB. Developing DNA vaccines that call to dendritic cells. J Clin Invest 2004;114:1241-4.
19. Berger E, Soldati R, Huebener N, Hohn O, Stermann A, Durmus T, et al. Salmonella SL7207 application is the most effective DNA vaccine delivery method for successful tumor eradication in a murine model for neuroblastoma. Cancer Lett 2013;331:167-73.
20. Li Z, Yin PH, Yang SS, Li QY, Chang T, Fang L, et al. Recombinant attenuated Salmonella typhimurium carrying a plasmid co-expressing ENDOVEGI151 and survivin siRNA inhibits the growth of breast cancer in vivo. Mol Med Rep 2013;7:1215-22.
21. Chen J, Lin M, Li N, Lin L, She F. Therapeutic vaccination with Salmonelladelivered codon-optimized outer inflammatory protein DNA vaccine enhances protection in Helicobacter pylori infected mice. Vaccine 2012;30:5310-5.
22. Gardlik R, Bartonova A, Celec P. Therapeutic DNA vaccination and RNA interference in inflammatory bowel disease. Int J Mol Med 2013;32:492-6.
23. Darji A, Guzman CA, Gerstel B, Wachholz P, Timmis KN, Wehland J, et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 1997;91:765-75.
24. Cochlovius B, Stassar MJ, Schreurs MW, Benner A, Adema GJ. Oral DNA vaccination: Antigen uptake and presentation by dendritic cells elicits protective immunity. Immunol Lett 2002;80:89-96.
25. Zhang J, DeMasi L, John B, ChenW, Schifferli DM. Improved delivery of the OVA-CD4 peptide to T helper cells by polymeric surface display on Salmonella. Microb Cell Fact 2014;13:80.
26. Barat S, Willer Y, Rizos K, Claudi B, Maze A, Schemmer AK, et al. Immunity to intracellular Salmonella depends on surface-associated antigens. PLoS Pathog 2012;8:e1002966.
27. Villarreal B, Mastroeni P, de Hormaeche, RD, Hormaeche CE. Proliferative and T-cell specific interleukin (IL-2/IL-4) production responses in spleen cells from mice vaccinated with aroA live attenuated Salmonella vaccines. Microb Pathog 1992;13:305-15.
28. Iho S, Maeyama J, Suzuki F. CpG oligodeoxynucleotides as mucosal adjuvants. Hum Vaccin Immunother 2015;11:755-60.
29. Casali N, Konieczny M, Schmidt MA, Riley LW. Invasion activity of a Mycobacterium tuberculosis peptide presented by the Escherichia coli AIDA autotransporter. Infect Immun 2002;70:6846-52.
30. Hoiseth SK, Stocker BA. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 1981;291:238-9.
31. Chen H, Schifferli DM.Comparison of a fimbrial versus an autotransporter display system for viral epitopes on an attenuated Salmonella vaccine vector. Vaccine 2007;25:1626-33.
32. Gupta SK, Smita S, Sarangi AN, Srivastava M, Akhoon BA, Rahman Q, et al. In silico CD4+ T-cell epitope prediction and HLA distribution analysis for the potential proteins of Neisseria meningitidis Serogroup B-a clue for vaccine development. Vaccine 2010;28:7092-7.
33. Konieczny MP, Suhr M, Noll A, Autenrieth IB, Alexander Schmidt M. Cell surface presentation of recombinant (poly-) peptides including functional T-cell epitopes by the AIDA autotransporter system. FEMS Immunol Med Microbiol 2000;27:321-32.
34. Kramer U, Rizos K, Apfel H, Autenrieth IB, Lattemann CT. Autodisplay: development of an efficacious system for surface display of antigenic determinants in Salmonella vaccine strains. Infect Immun 2003;71: 1944-52.
35. Ruiz-Perez F, Leon-Kempis R, Santiago-Machuca A, Ortega-Pierres G, Barry E, Levine M, et al. Expression of the Plasmodium falciparum immunodominant epitope (NANP)(4) on the surface of Salmonella enterica using the autotransporter MisL. Infect Immun 2002;70:3611-20.
36. Maurer J, Jose J, Meyer TF. Characterization of the essential transport function of the AIDA-I autotransporter and evidence supporting structural predictions. J Bacteriol 1999;181:7014-20.
37. Jose J, Bernhardt R, Hannemann F. Cellular surface display of dimeric Adx and whole cell P450-mediated steroid synthesis on E. coli. J Biotechnol 2002;95:257-68.
38. TosoliniM, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011;71:1263-71.
39. Punt S, Langenhoff JM, Putter H, Fleuren GJ, Gorter A, Jordanova ES. The correlations between IL-17 vs. Th17 cells and cancer patient survival: A systematic review. Oncoimmunology 2015;4:e984547.
40. Kang TH, Kim KW, Bae HC, Seong SY, Kim TW. Enhancement of DNA vaccine potency by antigen linkage to IFN-gamma-inducible protein-10. Int J Cancer 2011;128:702-14.
41. Shah MA, Ali Z, Ahmad R, Qadri I, Fatima K, He N. DNA mediated vaccines delivery through nanoparticles. J Nanosci Nanotechnol 2015;15:41-53.
42. Taylor N, Bahunde F, Thompson A, Yu JS, Jacobs WR Jr., Letvin NL, et al. Enhanced priming of adaptive immunity by Mycobacterium smegmatis mutants with high-level protein secretion. Clin Vaccine Immunol 2012;19:1416-25.
43. Voltan R, Castaldello A, Brocca-Cofano E, De Michele, R, Triulzi C, Altavilla G, et al. Priming with a very low dose of DNA complexed with cationic block copolymers followed by protein boost elicits broad and long-lasting antigen-specific humoral and cellular responses in mice. Vaccine 2009;27:4498-507.
44. Tomita Y, Yuno A, Tsukamoto H, Senju S, Kuroda Y, Hirayama M, et al. Identification of immunogenic LY6K long peptide encompassing both CD4+ and CD8+ T-cell epitopes and eliciting CD4+ T-cell immunity in patients with malignant disease. Oncoimmunology 2014;3:e28100.